NCT06697366View on ClinicalTrials.gov

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

May 20, 2026

Study Completion Date

November 20, 2026

Conditions
Gastric Cancer
Interventions
DRUG

Irinotecan liposome injection Ⅱ

56.6 mg/m2，Q3W

DRUG

Sintilimab

200mg，Q3W

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT06697366 - Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer | Biotech Hunter | Biotech Hunter